Covered recipient · General Payments record
JAVED BUTLER
Allopathic & Osteopathic Physicians Internal Medicine Advanced Heart Failure and Transplant Cardiology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$567,484.36
175 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $456,656.75 | 53 |
| Travel and Lodging | $57,335.13 | 55 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $42,570.00 | 12 |
| Honoraria | $7,600.00 | 1 |
| Food and Beverage | $3,322.48 | 54 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Boehringer Ingelheim International GmbH | $139,494.50 | 21 |
| Anumana, Inc. | $99,000.00 | 3 |
| Merck Sharp & Dohme LLC | $65,098.90 | 32 |
| Impulse Dynamics (USA) Inc. | $60,978.77 | 6 |
| Boehringer Ingelheim RCV GmbH & Co KG | $38,760.04 | 8 |
| Edwards Lifesciences Corporation | $34,098.85 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $27,390.34 | 22 |
| Abbott Laboratories | $17,463.71 | 14 |
| Amgen Inc. | $14,633.00 | 6 |
| Novo Nordisk AS | $11,589.80 | 5 |
| Novo Nordisk Inc | $10,708.77 | 7 |
| E.R. Squibb & Sons, L.L.C. | $8,737.00 | 5 |
| RECORDATI_RARE_DISEASES_INC. | $8,320.96 | 4 |
| IDORSIA PHARMACEUTICALS US INC | $6,440.00 | 1 |
| Lilly USA, LLC | $5,250.00 | 2 |
| ZOLL Circulation Inc | $5,238.49 | 5 |
| Bayer Healthcare Pharmaceuticals Inc. | $3,500.00 | 1 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $3,000.00 | 2 |
| Medtronic, Inc. | $2,082.39 | 7 |
| Lexicon Pharmaceuticals, Inc. | $1,593.67 | 2 |
| Daiichi Sankyo Inc. | $1,347.76 | 2 |
| AstraZeneca UK Limited | $1,092.13 | 2 |
| Chugai Pharmaceutical Co., Ltd. | $805.00 | 1 |
| Novartis Pharmaceuticals Corporation | $792.00 | 1 |
| CSL Behring | $68.28 | 1 |
Page 3 of 4; records 101–150 of 175 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JAVED BUTLER
NPI 1639100928 · CMS profile ID 73926
Allopathic & Osteopathic Physicians / Internal Medicine / Advanced Heart Failure and Transplant Cardiology
JACKSON, MS
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 4; records 101–150 of 175 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1639100928?year=2025&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JAVED BUTLER, NPI 1639100928, CMS profile ID 73926. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 175 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1639100928?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). JAVED BUTLER, NPI 1639100928, CMS profile ID 73926. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 175 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1639100928?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- JAVED BUTLER, NPI 1639100928, CMS profile ID 73926, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 175 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1639100928?year=2025&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
175 matching records · $567,484.36 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 175.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | $64.99 | 06/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1237999088 | CMS |
| Merck Sharp & Dohme LLC | $306.07 | 06/03/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238033940 | CMS |
| Merck Sharp & Dohme LLC | $54.99 | 06/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238036610 | CMS |
| Merck Sharp & Dohme LLC | $60.01 | 06/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238040423 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,200.00 | 06/02/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222898725 | CMS |
| Merck Sharp & Dohme LLC | $130.00 | 06/02/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238000000 | CMS |
| Merck Sharp & Dohme LLC | $306.07 | 06/02/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238002184 | CMS |
| Merck Sharp & Dohme LLC | $413.07 | 06/02/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238004246 | CMS |
| Merck Sharp & Dohme LLC | $306.07 | 06/02/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238009590 | CMS |
| Anumana, Inc. | $11,000.00 | 05/31/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248579006 | CMS |
| Anumana, Inc. | $11,000.00 | 05/31/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250216975 | CMS |
| RECORDATI_RARE_DISEASES_INC. | $30.73 | 05/31/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1181713326 | CMS |
| RECORDATI_RARE_DISEASES_INC. | $7,600.00 | 05/31/2025 | Honoraria | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1181713328 | CMS |
| RECORDATI_RARE_DISEASES_INC. | $52.27 | 05/31/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1181713330 | CMS |
| RECORDATI_RARE_DISEASES_INC. | $637.96 | 05/31/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1181713332 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $195.95 | 05/29/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222899009 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $150.72 | 05/29/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222899011 | CMS |
| Merck Sharp & Dohme LLC | $64.99 | 05/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1237996196 | CMS |
| Merck Sharp & Dohme LLC | $191.99 | 05/29/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238004042 | CMS |
| Merck Sharp & Dohme LLC | $55.00 | 05/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238037554 | CMS |
| Merck Sharp & Dohme LLC | $60.00 | 05/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238039046 | CMS |
| Merck Sharp & Dohme LLC | $130.00 | 05/28/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238005546 | CMS |
| Merck Sharp & Dohme LLC | $383.98 | 05/28/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238033606 | CMS |
| Merck Sharp & Dohme LLC | $333.78 | 05/28/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238040013 | CMS |
| Abbott Laboratories | $352.49 | 05/23/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1241100813 | CMS |
| Abbott Laboratories | $352.49 | 05/23/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1241100817 | CMS |
| Abbott Laboratories | $9.02 | 05/23/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1241101279 | CMS |
| Boehringer Ingelheim RCV GmbH & Co KG | $2,655.00 | 05/19/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1214256955 | CMS |
| AstraZeneca UK Limited | $18.13 | 05/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202913272 | CMS |
| Chugai Pharmaceutical Co., Ltd. | $805.00 | 05/18/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211521743 | CMS |
| Lexicon Pharmaceuticals, Inc. | $1,500.00 | 05/16/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248066171 | CMS |
| Merck Sharp & Dohme LLC | $78.89 | 05/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1237995426 | CMS |
| Merck Sharp & Dohme LLC | $8,747.81 | 05/16/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238040015 | CMS |
| Novo Nordisk Inc | $111.27 | 05/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1188730371 | CMS |
| Novo Nordisk Inc | $1,570.00 | 05/08/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1189167823 | CMS |
| Boehringer Ingelheim International GmbH | $885.00 | 05/02/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1215870812 | CMS |
| Novartis Pharmaceuticals Corporation | $792.00 | 04/27/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200094202 | CMS |
| Boehringer Ingelheim International GmbH | $5,310.00 | 04/24/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1215870767 | CMS |
| Boehringer Ingelheim RCV GmbH & Co KG | $7,965.00 | 04/06/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1214256957 | CMS |
| Novo Nordisk AS | $785.00 | 04/01/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1189187039 | CMS |
| Amgen Inc. | $79.86 | 03/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228632022 | CMS |
| Novo Nordisk AS | $328.95 | 03/28/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1189186147 | CMS |
| Novo Nordisk AS | $10,008.75 | 03/28/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1189186265 | CMS |
| Novo Nordisk AS | $368.94 | 03/28/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1189187019 | CMS |
| Novo Nordisk AS | $98.16 | 03/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1189187359 | CMS |
| Merck Sharp & Dohme LLC | $37,515.00 | 03/24/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238036396 | CMS |
| Edwards Lifesciences Corporation | $232.64 | 03/23/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225306347 | CMS |
| ZOLL Circulation Inc | $1,000.00 | 03/13/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1173763609 | CMS |
| Boehringer Ingelheim International GmbH | $410.50 | 03/12/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1215870709 | CMS |
| Boehringer Ingelheim International GmbH | $17.45 | 03/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1215870715 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $57,270.03 | 42 |
| PY2024 | Recipient | $31,923.84 | 6 |
| PY2023 | Recipient | $19,843.63 | 8 |
| PY2022 | Recipient | $26,100.00 | 5 |
| PY2021 | Recipient | $50,965.50 | 6 |
| PY2020 | Recipient | $137,197.00 | 9 |
| PY2019 | Recipient | $8,225.00 | 3 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
42 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Recipient | CVRx, Inc. | $5,400.00 | 12/17/2025 | Covered Recipient Physician | Not supplied | No dispute reported | 06/30/2026 | 1228698920 |
| Recipient | Boehringer Ingelheim International GmbH | $150.61 | 10/28/2025 | Covered Recipient Physician | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220657386 |
| Recipient | Boehringer Ingelheim International GmbH | $11.63 | 10/28/2025 | Covered Recipient Physician | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220657388 |
| Recipient | Boehringer Ingelheim International GmbH | $26.17 | 10/28/2025 | Covered Recipient Physician | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220657390 |
| Recipient | Boehringer Ingelheim International GmbH | $150.61 | 10/28/2025 | Covered Recipient Physician | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220657392 |
| Recipient | Boehringer Ingelheim International GmbH | $49.74 | 10/28/2025 | Covered Recipient Physician | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220657394 |
| Recipient | Boehringer Ingelheim International GmbH | $34.32 | 10/28/2025 | Covered Recipient Physician | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220657398 |
| Recipient | Boehringer Ingelheim International GmbH | $11.63 | 10/28/2025 | Covered Recipient Physician | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220657400 |
| Recipient | Bayer Healthcare Pharmaceuticals Inc. | $2,500.00 | 10/24/2025 | Covered Recipient Physician | REDEFINE-HF Study #22438 | No dispute reported | 06/30/2026 | 1225400814 |
| Recipient | Bayer Healthcare Pharmaceuticals Inc. | $2,500.00 | 10/24/2025 | Covered Recipient Physician | REDEFINE-HF Study #22438 | No dispute reported | 06/30/2026 | 1225400816 |
| Recipient | Bayer Healthcare Pharmaceuticals Inc. | $2,500.00 | 10/24/2025 | Covered Recipient Physician | REDEFINE-HF Study #22438 | No dispute reported | 06/30/2026 | 1225400818 |
| Recipient | Bayer Healthcare Pharmaceuticals Inc. | $2,500.00 | 10/24/2025 | Covered Recipient Physician | Finality Study #22618 | No dispute reported | 06/30/2026 | 1225400820 |
| Recipient | Bayer Healthcare Pharmaceuticals Inc. | $2,500.00 | 10/24/2025 | Covered Recipient Physician | Finality Study #22618 | No dispute reported | 06/30/2026 | 1225400822 |
| Recipient | Bayer Healthcare Pharmaceuticals Inc. | $2,500.00 | 10/24/2025 | Covered Recipient Physician | Finality Study #22618 | No dispute reported | 06/30/2026 | 1225400824 |
| Recipient | Boehringer Ingelheim International GmbH | $22.99 | 08/28/2025 | Covered Recipient Physician | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220657402 |
| Recipient | Boehringer Ingelheim International GmbH | $10,435.41 | 07/08/2025 | Covered Recipient Physician | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220657396 |
| Recipient | Boehringer Ingelheim International GmbH | $303.60 | 05/07/2025 | Covered Recipient Physician | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220657338 |
| Recipient | Boehringer Ingelheim International GmbH | $20.00 | 05/07/2025 | Covered Recipient Physician | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220657346 |
| Recipient | Boehringer Ingelheim International GmbH | $57.19 | 05/07/2025 | Covered Recipient Physician | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220657348 |
| Recipient | Boehringer Ingelheim International GmbH | $40.45 | 05/07/2025 | Covered Recipient Physician | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220657350 |
| Recipient | Boehringer Ingelheim International GmbH | $38.36 | 05/07/2025 | Covered Recipient Physician | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220657352 |
| Recipient | Boehringer Ingelheim International GmbH | $124.99 | 05/07/2025 | Covered Recipient Physician | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220657354 |
| Recipient | Boehringer Ingelheim International GmbH | $263.22 | 05/07/2025 | Covered Recipient Physician | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220657356 |
| Recipient | Boehringer Ingelheim International GmbH | $60.06 | 05/07/2025 | Covered Recipient Physician | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220657358 |
| Recipient | Boehringer Ingelheim International GmbH | $62.39 | 05/07/2025 | Covered Recipient Physician | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220657360 |
| Recipient | Boehringer Ingelheim International GmbH | $20.00 | 05/07/2025 | Covered Recipient Physician | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220657362 |
| Recipient | Boehringer Ingelheim International GmbH | $123.97 | 05/07/2025 | Covered Recipient Physician | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220657364 |
| Recipient | Boehringer Ingelheim International GmbH | $315.32 | 05/06/2025 | Covered Recipient Physician | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220657344 |
| Recipient | Boehringer Ingelheim International GmbH | $174.80 | 04/02/2025 | Covered Recipient Physician | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220657340 |
| Recipient | Boehringer Ingelheim International GmbH | $267.25 | 04/02/2025 | Covered Recipient Physician | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220657342 |
| Recipient | Boehringer Ingelheim International GmbH | $79.88 | 03/28/2025 | Covered Recipient Physician | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220657384 |
| Recipient | Boehringer Ingelheim International GmbH | $100.00 | 03/12/2025 | Covered Recipient Physician | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220657368 |
| Recipient | Boehringer Ingelheim International GmbH | $373.89 | 03/12/2025 | Covered Recipient Physician | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220657370 |
| Recipient | Boehringer Ingelheim International GmbH | $373.89 | 03/12/2025 | Covered Recipient Physician | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220657372 |
| Recipient | Boehringer Ingelheim International GmbH | $12.10 | 03/12/2025 | Covered Recipient Physician | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220657374 |
| Recipient | Boehringer Ingelheim International GmbH | $33.79 | 03/12/2025 | Covered Recipient Physician | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220657376 |
| Recipient | Boehringer Ingelheim International GmbH | $57.78 | 03/12/2025 | Covered Recipient Physician | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220657378 |
| Recipient | Boehringer Ingelheim International GmbH | $33.79 | 03/12/2025 | Covered Recipient Physician | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220657380 |
| Recipient | Boehringer Ingelheim International GmbH | $316.00 | 03/12/2025 | Covered Recipient Physician | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220657382 |
| Recipient | Medtronic, Inc. | $8,250.00 | 03/07/2025 | Covered Recipient Physician | ALLEVIATE-HF | No dispute reported | 06/30/2026 | 1192317560 |
| Recipient | Boehringer Ingelheim International GmbH | $10,199.20 | 02/04/2025 | Covered Recipient Physician | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220657366 |
| Recipient | ZOLL Circulation Inc | $4,275.00 | 01/31/2025 | Covered Recipient Physician | Not supplied | No dispute reported | 06/30/2026 | 1173764171 |